ERBB2 and cancer: By blocking the ErbB2 survival pathway, trastuzumab reduces the cancer mass along with being also severely cardiotoxic and increasing the risk of cardiovascular events whose frequency is highly variable and depends on trastuzumab association with other anticancer drugs (e.g., with or without concomitant or sequential anthracyclines), on patient age and on comorbidities [95–104].